Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments

References

• Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J. 2022;43:3925–3946.
   PubMed Web of Science ®Google Scholar
• Reyes-Soffer G, Ginsberg HN, Berglund L, et al. American heart association council on arteriosclerosis, thrombosis and vascular biology; council on cardiovascular radiology and intervention; and council on peripheral vascular disease. lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2022;42:e48–e60.
   PubMed Web of Science ®Google Scholar
• Erqou S, Kaptoge S, PL P, et al., Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–423.
   PubMed Web of Science ®Google Scholar
• Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392:1311–1320.
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. PROCARDIS consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–2528.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–2339.
   PubMed Web of Science ®Google Scholar
• Investigators AIM-HIG-H, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
   PubMed Web of Science ®Google Scholar
• MJ L, Haynes R, JC H, et al.; HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
   PubMed Web of Science ®Google Scholar
• Szarek M, Bittner VA, Aylward P, et al. ODYSSEY OUTCOMES Investigators. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020;41:4245–4255.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.
   PubMed Web of Science ®Google Scholar
• Vogt A. Lipoprotein(a)-apheresis in the light of new drug developments. Atheroscler Suppl. 2017;30:38–43.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8:538–554.
   PubMed Web of Science ®Google Scholar
• Hadi A, Askarpour M, Ziaei R, et al. Impact of flaxseed supplementation on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2020;34:1599–1608.
   PubMed Web of Science ®Google Scholar
• Fatahi S, Kord-Varkaneh H, Talaei S, et al. Impact of phytosterol supplementation on plasma lipoprotein(a) and free fatty acid (FFA) concentrations: a systematic review and meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2019;29:1168–1175.
   PubMed Web of Science ®Google Scholar
• Santos HO, Kones R, Rumana U, et al. Lipoprotein(a): current evidence for a physiologic role and the effects of nutraceutical strategies. Clin Ther. 2019;41:1780–1797.
   PubMed Web of Science ®Google Scholar
• Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388:2239–2253.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. AKCEA-APO(a)-LRx study investigators. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244–255.
   PubMed Web of Science ®Google Scholar
• Karwatowska-Prokopczuk E, Clouet-Foraison N, Xia S, et al. Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen. Atherosclerosis. 2021;324:102–108.
   PubMed Web of Science ®Google Scholar
• (cited 2022 Oct 11)https://clinicaltrials.gov/ct2/show/NCT04023552
   Google Scholar
• Koren MJ, Moriarty PM, Baum SJ, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med. 2022;28:96–103.
   PubMed Web of Science ®Google Scholar
• Sohn W, Winkle P, Neutel J, et al. Pharmacokinetics, pharmacodynamics, and tolerability of olpasiran in healthy Japanese and Non-Japanese participants: results from a phase I, single-dose, open-label study. Clin Ther. 2022;44:1237–1247.
   PubMed Web of Science ®Google Scholar
• (cited 2022 Oct 22. https://clinicaltrials.gov/ct2/show/NCT05581303
   Google Scholar
• Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA. 2022;327:1679–1687.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC scientific document group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.
   PubMed Web of Science ®Google Scholar
• Ray KK, Bays HE, Catapano AL, et al. CLEAR harmony trial. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022–1032.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Rosenson RS, Reeskamp LF, et al. ELIPSE HoFH investigators. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711–720.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without Aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–1330.
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Fiolet ATL, Mosterd A, et al. LoDoCo2 trial investigators. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838–1847.
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. ESC national cardiac societies; ESC scientific document group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–3337.
   PubMedGoogle Scholar